Mostrar el registro sencillo del ítem

dc.contributor.authorLiu, Xiaoyan
dc.contributor.authorSwen, Jesse J
dc.contributor.authorBoven, Epie
dc.contributor.authorCastellano, Daniel
dc.contributor.authorGelderblom, Hans
dc.contributor.authorMathijssen, Ron H J
dc.contributor.authorRodriguez Antona, Cristina 
dc.contributor.authorGarcía-Donas, Jesus
dc.contributor.authorRini, Brian I
dc.contributor.authorGuchelaar, Henk-Jan
dc.date.accessioned2019-10-09T11:51:44Z
dc.date.available2019-10-09T11:51:44Z
dc.date.issued2017-01-03
dc.identifier.citationOncotarget. 2017 ;8(1):1204-1212es_ES
dc.identifier.issn1949-2553es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8486
dc.description.abstractVEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Hereafter, the association of both single nucleotide polymorphisms (SNPs) with PFS/OS was confirmed in two independent mRCC cohorts. The aim of the current study was to validate the associations of both SNPs with sunitinib outcome in three independent well-characterized cohorts (SUTOX, CCF and SOGUG) including 286 sunitinib-treated mRCC patients, as well as to perform a meta-analysis of current and published data combined. We found that rs9582036 and rs9554320 showed a significant association with sunitinib PFS in the CCF cohort (HR: 0.254, 95%CI: 0.092-0.703; P=0.008 and HR: 0.430, 95%CI: 0.200-0.927; P=0.031, respectively). Patients with the variant genotype of rs9582036 and rs9554320 had a shorter median PFS. No significant association of both SNPs with sunitinib PFS or OS was detected in either the SUTOX or SOGUG cohort. After the combination of all available data into a meta-analysis, the association of both SNPs with sunitinib PFS or OS did not achieve the threshold for statistical significance. Our findings suggest that, although VEGFR1 rs9582036 and rs9554320 are involved in sunitinib therapy outcome, its clinical use as biomarkers for prediction of sunitinib outcome in mRCC patients is limited, due to inconsistent findings when analyzing all existing studies together.es_ES
dc.description.sponsorshipPfizer supports this research by an unrestricted research grant. Xiaoyan Liu is supported by the Chinese Scholarship Council (No. 201406220186).es_ES
dc.language.isoenges_ES
dc.publisherImpact Journals es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectVEGFR1es_ES
dc.subjectMeta-analysises_ES
dc.subjectMetastatic renal cell carcinomaes_ES
dc.subjectSunitinibes_ES
dc.subjectValidation studyes_ES
dc.subject.meshAlleles es_ES
dc.subject.meshAntineoplastic Agents es_ES
dc.subject.meshCarcinoma, Renal Cell es_ES
dc.subject.meshGene Frequency es_ES
dc.subject.meshGenotype es_ES
dc.subject.meshHumans es_ES
dc.subject.meshIndoles es_ES
dc.subject.meshKidney Neoplasms es_ES
dc.subject.meshNeoplasm Metastasis es_ES
dc.subject.meshPolymorphism, Single Nucleotidees_ES
dc.subject.meshPrognosis es_ES
dc.subject.meshProportional Hazards Models es_ES
dc.subject.meshPyrroles es_ES
dc.subject.meshSunitinib es_ES
dc.subject.meshTreatment Outcome es_ES
dc.subject.meshVascular Endothelial Growth Factor Receptor-1 es_ES
dc.subject.meshGenetic Variation es_ES
dc.titleMeta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patientses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID27901483es_ES
dc.format.volume8es_ES
dc.format.number1es_ES
dc.format.page1204-1212es_ES
dc.identifier.doi10.18632/oncotarget.13597es_ES
dc.contributor.funderPfizer 
dc.contributor.funderChina Scholarship Council
dc.description.peerreviewedes_ES
dc.identifier.e-issn1949-2553es_ES
dc.relation.publisherversionhttps://doi.org/10.18632/oncotarget.13597.es_ES
dc.identifier.journalOncotargetes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Cáncer Endocrino Hereditarioes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional